NEW YORK, NY and Tel Aviv, ISRAEL, Sept. 16, 2022 (GLOBE NEWSWIRE) — through NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a complete medical diagnostics and associated options firm, right now introduced that Michael Irvin has agreed to turn out to be the Sports Ambassador for the Company’s 3CL Pharma’s majority-owned subsidiary’s #TolloUp advertising and marketing marketing campaign for 3CL protease inhibitor immune help complement Tollovid™. A latest market analysis examine confirmed that 90%+ of each acute an infection and Long COVID clients indicated they benefitted from Tollovid™. Tollovid has been Informed Sports licensed as not having any efficiency enhancing or banned substances and is secure for athletes to make use of whereas competing.
“We know that if you want to win, you have to stay in the game and be able to be at your best while training and competing. After seeing the data and experiencing Tollovid for myself, I feel very comfortable recommending this product to athletes or anyone who is consistently on the move like I am and who is looking for immune support in this pandemic world in order to be able to compete at a championship level,” stated NFL Hall of Famer and Tollovid Sports Ambassador, Michael Irvin.
“Michael Irvin is one of the greatest NFL players of all time and an all-time competitor,” stated Gerald E. Commissiong, President & CEO of Todos Medical. “With athletic competition in full swing this fall sports season and school back in session, it has become more important than ever to be proactive in protecting yourself and your loved ones. With this in mind, Tollovid is an ideal solution to help support healthy immune function and guard against infections that can derail a season.”
To be taught extra in regards to the 3CL protease in SARS-CoV-2 replication, please go to www.3clpro.com. To buy Tollovid please go to Amazon or www.MyTollovid.com.
About Tollovid™ and Tollovid Daily™
Tollovid and Tollovid Daily are oral dietary complement merchandise produced from pure components that assist help and keep wholesome immune perform and now have potent 3CL protease inhibition properties primarily based upon in vitro purposeful assays that present sturdy inhibition of 3CL protease exercise. Tollovid and Tollovid Daily bind to the energetic website of the 3CL protease. Tollovid has a 5-day dosing routine, with 4 doses of 3 capsules taken every day that gives most immune help. Tollovid Daily is a every day immune help product with a dosing routine of twice every day. Preliminary information from an ongoing IRB-waived examine of clients who used the merchandise to help with their COVID and Long COVID have been not too long ago introduced.
To buy Tollovid please go to Amazon or www.MyTollovid.com.
About Tollovir™
Tollovir is an oral 3CL protease inhibitor and anti-cytokine therapeutic candidate focusing on the Nidovirus group of viruses that features coronaviruses such as SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is produced from all pure components which are certified to make sure sturdy inhibition of the 3CL protease in vitro, as properly as sturdy anti-cytokine exercise. Tollovir has efficiently accomplished a Phase 2 medical trial in Israel for the therapy of sufferers hospitalized with COVID-19. Tollovir will probably be developed for the therapy of hospitalized COVID-19 (extreme and significant), reasonable COVID-19, Long COVID and, doubtlessly, pediatric COVID-19.
About Todos Medical Ltd.
Founded in Rehovot, Israel with places of work in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic options for the early detection of a range of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening expertise utilizing peripheral blood evaluation that examines most cancers’s affect on the immune system, in search of biochemical adjustments in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening assessments, TMB-1 and TMB-2 have acquired a CE mark in Europe. Todos not too long ago acquired U.S.-based medical diagnostics firm Provista Diagnostics, Inc. to achieve rights to its Alpharetta, Georgia-based CLIA/CAP licensed lab at the moment performing PCR COVID testing, Long COVID Panel analyses, and Provista’s proprietary commercial-stage Videssa® breast most cancers blood take a look at. More data on Provista is out there at www.provistadx.com.
Todos can be creating blood assessments for the early detection of neurodegenerative issues, such as Alzheimer’s illness. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood take a look at that determines the power of peripheral blood lymphocytes (PBLs) and monocytes to face up to an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that sure ailments, most notably Alzheimer’s illness, are the consequence of compromised mobile equipment that results in aberrant cell cycle re-entry by neurons, which then results in apoptosis. LymPro is exclusive within the use of peripheral blood lymphocytes as a surrogate for neuronal cell perform, suggesting a standard relationship between PBLs and neurons within the mind.
Todos shaped the Israeli-based majority-owned three way partnership 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the mental property surrounding 3CL protease–primarily based diagnostic testing and improvement of 3CL protease botanical and pharmaceutical inhibitors that concentrate on a basic reproductive mechanism of coronaviruses. 3CL Pharma, via Todos’ model, has commercialized the 3CL protease inhibitor immune help dietary complement Tollovid™ within the United States, is creating the twin mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, whereas additionally creating the 3CL protease diagnostic TolloTest™.
To buy Tollovid please go to Amazon or www.MyTollovid.com. For extra data, please go to https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained on this press launch could represent forward-looking statements. For instance, forward-looking statements are used when discussing our anticipated medical improvement packages and medical trials. These forward-looking statements are primarily based solely on present expectations of administration, and are topic to important dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements, together with the dangers and uncertainties associated to the progress, timing, value, and outcomes of medical trials and product improvement packages; difficulties or delays in acquiring regulatory approval or patent safety for product candidates; competitors from different biotechnology corporations; and our skill to acquire further funding required to conduct our analysis, improvement and commercialization actions. In addition, the next components, amongst others, may trigger precise outcomes to vary materially from these described within the forward-looking statements: adjustments in expertise and market necessities; delays or obstacles in launching our medical trials; adjustments in laws; lack of ability to well timed develop and introduce new applied sciences, merchandise and purposes; lack of validation of our expertise as we progress additional and lack of acceptance of our strategies by the scientific group; lack of ability to retain or appeal to key staff whose information is important to the event of our merchandise; unexpected scientific difficulties which will develop with our course of; better value of last product than anticipated; loss of market share and strain on pricing ensuing from the competitors; and laboratory outcomes that don’t translate to equally good leads to actual settings, all of which may trigger the precise outcomes or efficiency to vary materially from these contemplated in such forward-looking statements. Except as in any other case required by legislation, Todos Medical doesn’t undertake any obligation to publicly launch any revisions to those forward-looking statements to mirror occasions or circumstances after the date hereof or to mirror the prevalence of unanticipated occasions. For a extra detailed description of the dangers and uncertainties affecting Todos Medical, please discuss with its experiences filed every now and then with the U.S. Securities and Exchange Commission.
Todos Corporate Contact:
Daniel Hirsch CFO
Todos Medical
917-983-4229 x 104
[email protected]
Todos Press Contact:
Kyle Kappmeier
JConnelly
Vice President
973-975-7827
[email protected]
